Effects of nifedipine on hepatic drug oxidation

T. H. Dickinson, J. M. Egan, Darrell R. Abernethy

Research output: Contribution to journalArticle

Abstract

To determine whether inhibition of drug oxidation is a general property of all calcium antagonist drugs or just of a few, we measured effects of therapeutic doses of nifedipine on antipyrine biotransformation. Antipyrine was administered in random order to 10 subjects while drug-free and while taking nifedipine 30 mg 3 times daily. Total antipyrine clearance (means ± SE, 43.1 ± 4.8 control vs. 50.4 ± 6.5 ml/min; NS) tended to increase but not significantly. Elimination half-life decreased slightly (13.7 ± 1.0 control vs. 11.7 ± 0.9; p <0.05). Antipyrine metabolite excretion, measured to evaluate selective oxidative pathways, was unaffected by concurrent nifedipine administration. Nifedipine in therapeutic doses had no effect on antipyrine oxidation, unlike verapamil and diltiazem, both of which inhibit hepatic drug oxidation. Inhibition of drug oxidation appears not to be a general property of calcium antagonist drugs.

Original languageEnglish (US)
Pages (from-to)405-410
Number of pages6
JournalPharmacology
Volume36
Issue number6
DOIs
StatePublished - 1988
Externally publishedYes

Fingerprint

Antipyrine
Nifedipine
Liver
Pharmaceutical Preparations
Calcium
Diltiazem
Therapeutic Uses
Biotransformation
Verapamil
Half-Life

Keywords

  • Antipyrine
  • Calcium antagonist inhibition
  • Cytochrome P-450
  • Hepatic drug oxidation
  • Nifedipine

ASJC Scopus subject areas

  • Pharmacology

Cite this

Dickinson, T. H., Egan, J. M., & Abernethy, D. R. (1988). Effects of nifedipine on hepatic drug oxidation. Pharmacology, 36(6), 405-410. https://doi.org/10.1159/000138329

Effects of nifedipine on hepatic drug oxidation. / Dickinson, T. H.; Egan, J. M.; Abernethy, Darrell R.

In: Pharmacology, Vol. 36, No. 6, 1988, p. 405-410.

Research output: Contribution to journalArticle

Dickinson, TH, Egan, JM & Abernethy, DR 1988, 'Effects of nifedipine on hepatic drug oxidation', Pharmacology, vol. 36, no. 6, pp. 405-410. https://doi.org/10.1159/000138329
Dickinson, T. H. ; Egan, J. M. ; Abernethy, Darrell R. / Effects of nifedipine on hepatic drug oxidation. In: Pharmacology. 1988 ; Vol. 36, No. 6. pp. 405-410.
@article{14b406a511bf4aa1b6bd71cceca6f757,
title = "Effects of nifedipine on hepatic drug oxidation",
abstract = "To determine whether inhibition of drug oxidation is a general property of all calcium antagonist drugs or just of a few, we measured effects of therapeutic doses of nifedipine on antipyrine biotransformation. Antipyrine was administered in random order to 10 subjects while drug-free and while taking nifedipine 30 mg 3 times daily. Total antipyrine clearance (means ± SE, 43.1 ± 4.8 control vs. 50.4 ± 6.5 ml/min; NS) tended to increase but not significantly. Elimination half-life decreased slightly (13.7 ± 1.0 control vs. 11.7 ± 0.9; p <0.05). Antipyrine metabolite excretion, measured to evaluate selective oxidative pathways, was unaffected by concurrent nifedipine administration. Nifedipine in therapeutic doses had no effect on antipyrine oxidation, unlike verapamil and diltiazem, both of which inhibit hepatic drug oxidation. Inhibition of drug oxidation appears not to be a general property of calcium antagonist drugs.",
keywords = "Antipyrine, Calcium antagonist inhibition, Cytochrome P-450, Hepatic drug oxidation, Nifedipine",
author = "Dickinson, {T. H.} and Egan, {J. M.} and Abernethy, {Darrell R.}",
year = "1988",
doi = "10.1159/000138329",
language = "English (US)",
volume = "36",
pages = "405--410",
journal = "Pharmacology",
issn = "0031-7012",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Effects of nifedipine on hepatic drug oxidation

AU - Dickinson, T. H.

AU - Egan, J. M.

AU - Abernethy, Darrell R.

PY - 1988

Y1 - 1988

N2 - To determine whether inhibition of drug oxidation is a general property of all calcium antagonist drugs or just of a few, we measured effects of therapeutic doses of nifedipine on antipyrine biotransformation. Antipyrine was administered in random order to 10 subjects while drug-free and while taking nifedipine 30 mg 3 times daily. Total antipyrine clearance (means ± SE, 43.1 ± 4.8 control vs. 50.4 ± 6.5 ml/min; NS) tended to increase but not significantly. Elimination half-life decreased slightly (13.7 ± 1.0 control vs. 11.7 ± 0.9; p <0.05). Antipyrine metabolite excretion, measured to evaluate selective oxidative pathways, was unaffected by concurrent nifedipine administration. Nifedipine in therapeutic doses had no effect on antipyrine oxidation, unlike verapamil and diltiazem, both of which inhibit hepatic drug oxidation. Inhibition of drug oxidation appears not to be a general property of calcium antagonist drugs.

AB - To determine whether inhibition of drug oxidation is a general property of all calcium antagonist drugs or just of a few, we measured effects of therapeutic doses of nifedipine on antipyrine biotransformation. Antipyrine was administered in random order to 10 subjects while drug-free and while taking nifedipine 30 mg 3 times daily. Total antipyrine clearance (means ± SE, 43.1 ± 4.8 control vs. 50.4 ± 6.5 ml/min; NS) tended to increase but not significantly. Elimination half-life decreased slightly (13.7 ± 1.0 control vs. 11.7 ± 0.9; p <0.05). Antipyrine metabolite excretion, measured to evaluate selective oxidative pathways, was unaffected by concurrent nifedipine administration. Nifedipine in therapeutic doses had no effect on antipyrine oxidation, unlike verapamil and diltiazem, both of which inhibit hepatic drug oxidation. Inhibition of drug oxidation appears not to be a general property of calcium antagonist drugs.

KW - Antipyrine

KW - Calcium antagonist inhibition

KW - Cytochrome P-450

KW - Hepatic drug oxidation

KW - Nifedipine

UR - http://www.scopus.com/inward/record.url?scp=0023886871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023886871&partnerID=8YFLogxK

U2 - 10.1159/000138329

DO - 10.1159/000138329

M3 - Article

C2 - 3420161

AN - SCOPUS:0023886871

VL - 36

SP - 405

EP - 410

JO - Pharmacology

JF - Pharmacology

SN - 0031-7012

IS - 6

ER -